NCT06889909Active, not recruiting
Comparison of Once-Weekly Trelagliptin Vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes
Comparison of Efficacy of Once Weekly Dose of Trelagliptin Versus Once Daily Dose of Vildagliptin on the Levels of HbA1c in Type-2 Diabetes Patients
Source: ClinicalTrials.gov · Last updated 21 Mar 2025
Brief summary (registry, in English)
This randomized controlled trial evaluated the efficacy of once-weekly trelagliptin compared to once-daily vildagliptin in reducing HbA1c levels in patients with type 2 diabetes mellitus (T2DM). A total of 102 participants, aged 30-60 years with HbA1c levels between 7.5% and 9.5%, were enrolled and randomly assigned to either the trelagliptin or vildagliptin group. The primary outcome measured was the percentage of participants achieving an HbA1c level of less than 7% after three months of treatment. Secondary outcomes included the mean reduction in HbA1c levels from baseline. The study aimed to determine whether trelagliptin, with its once-weekly dosing regimen, could improve medication adherence and glycemic control compared to the conventional daily administration of vildagliptin. Data were analyzed using SPSS version 26.0, with independent t-tests and chi-square tests employed for statistical comparisons. Findings from this study contributed to the understanding of the clinical effectiveness of weekly versus daily DPP-4 inhibitors in the management of T2DM.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 102 (actual)
- First submitted
- 16 Mar 2025
- Start date
- 15 Dec 2024
- Primary completion date
- 15 Jun 2025
- Lead sponsor
- Lahore General Hospital
- Diseases
- Type 2 diabetes
- NCT number
- NCT06889909
What you commit to
- Study type: Interventional
- Participants enrolled: 102
- From 15 Dec 2024 to the primary completion date, 15 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of insulin or any antidiabetic drugs other than metformin within 3 months prior to the start of the study.
- Participation in another clinical trial within 30 days prior to enrollment.
Other illness
- Type 1 diabetes mellitus or a history of ketoacidosis.
- Significant cardiovascular disease, including recent myocardial infarction (within the last 6 months), unstable angina, or uncontrolled hypertension.
- Chronic kidney disease (stage 3 or worse) or hepatic or pancreatic dysfunction.
- Known hypersensitivity to trelagliptin, vildagliptin, or any components of their formulations.
- Any medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study.
- Participants for whom blood sugar control by insulin preparations is desired (for example, participants with severe ketosis, diabetic coma or precoma, type 1 diabetes mellitus, severe infection, or serious trauma before or after surgery).
Other
- Pregnant or breastfeeding or planning to become pregnant during the study duration.
- Participants with unstable proliferative diabetic retinopathy.
Who the study is looking for
- Adults aged 30-60 years.
- Both male and female.
- Diagnosed with type 2 diabetes mellitus.
- HbA1c levels between 7.5% and 9.5% at screening.
- Able to provide informed consent.
Age in the registry: 30 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lahore General Hospital, Lahore Coordinator of this site? Confirm its status | Lahore | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.